FDA Letter API

Integrated Health Concepts Inc.

Letter data

Company
Integrated Health Concepts Inc.
Recipient
Taylor Cline | Chief Executive Officer and President | Integrated Health Concepts Inc. | 720 Aerovista Place | Suite D | San Luis Obispo | , | CA | 93401-8726 | United States
Issue date
2022-01-18
Posted date
Not available
FDA office
Division of Pharmaceutical Quality Operations IV
Subject
Not available
Product
Drugs
CMS ID
610546
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Integrated Health Concepts Inc. MARCS-CMS 610546 — January 18, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL CONFIRMED DELIVERY Product: Drugs Recipient: Recipient Name Taylor Cline Recipient Title Chief Executive Officer and President Integrated Health Concepts Inc. 720 Aerovista Place Suite D San Luis Obispo , CA 93401-8726 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States Dear Mr. Taylor Cline: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL 610546) dated September 10, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV Content current as of: 02/02/2022 Regulated Product(s) Drugs